The global metals and mining industry outlook has changed from ‘positive’ to ‘stable’, with a new Moody’s Investors Service report finding that despite most metals prices exceeding historical marks, that doesn’t mean they will improve from current levels.
Wesana Health Commits Funding of $1.5 Million To Support MAPS’ Research Pipeline
Wesana looks to expand its TBI-based psychedelics research into MDMA, with a new research partnership with MAPS.
Cannabis Flower Now Available to Virginia Patients
Cannabis flower is now available to Virginia patients who can purchase up to four ounces per month, WRIC reports.
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
Atai affiliate, Perception Neuroscience is commencing a Phase 2a clinical trial of an R-ketamine medication for the treatment of depression.
Copper, aluminum prices up as inflation runs hot
A broad rally in base metals markets is gathering pace, with tight supply, logistical logjams and booming demand creating an inflationary storm that’s driving prices to multiyear highs.
Indian spot gold rate and silver price on Monday, Sep 13, 2021
Gold Price observed no change since yesterday and also, it was on par with the average gold price observed this week.
Why Psychedelic Medicine Cures Will Have Greater Profit Potential Than Big Pharma Bandaids
Big Pharma's business model for drug development is all about maximizing profits, not health. Psychedelic medicine can maximize profits AND health.
Silver seen tracking copper prices higher
As a keen observer of the silver market, something recently caught my eye concerning the relationship between silver and gold and silver and copper.
Gold, silver see steady price action ahead of U.S. inflation report
Gold and silver prices are not trading far from unchanged in early U.S. dealings Friday.
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
Atai Life Sciences seeks to integrate digital therapeutics into ketamine-based treatment for TRD, via its digital therapeutic platform, Introspect Digital Therapeutics.
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
Psychedelics media star, Hamilton Morris is joining Compass Pathways as a full-time consultant on psychedelics research.
Wesana Health Announces Closing of PsyTech Acquisition
Wesana Health closes on its acquisition of PsyTech, solidifying its business model as it seeks a U.S. listing.
